Weight Loss & Metabolic
Best Peptides for Stubborn & Visceral Fat: Evidence Ranked
A clinical-evidence ranking of the peptides that actually reduce visceral (belly) fat — one of the rare peptide topics with genuine Grade A human RCT proof — separating the FDA-approved and investigational incretin/GHRH drugs from the gray-market 'fat-loss' peptides that have none.
visceral fatbelly fatVAT reductionGHRH analogincretin peptides
The quick verdict
Visceral-fat reduction is one of the rare peptide topics with genuine Grade A human RCT evidence: tesamorelin is the only drug ever FDA-approved specifically to cut excess visceral abdominal fat, while tirzepatide, semaglutide and investigational retatrutide post the largest imaging-confirmed reductions — and the gray-market 'fat-loss' peptides have none.
- Best overall
- Tesamorelin — The only drug ever FDA-approved specifically to reduce excess visceral abdominal fat, with CT-measured visceral adipose tissue as the primary RCT endpoint and a 2026 five-RCT meta-analysis confirming the effect — though its approved evidence is confined to HIV-associated lipodystrophy.
- Best value
- Semaglutide — FDA-approved, widely available and the most broadly evidenced GLP-1 — robust ~27% visceral-fat reduction in the STEP 1 substudy plus a proven ~20% cut in major cardiovascular events, generally at lower cost than the newest agents.
- Best for Largest imaging-confirmed visceral-fat loss in the general (non-HIV) population
- Tirzepatide — The dual GIP/GLP-1 agonist produces the greatest MRI-confirmed visceral and liver-fat reductions outside HIV lipodystrophy, with an apparent targeted effect on visceral fat beyond what weight loss alone predicts.
How we evaluated
PeptideVox ranks each peptide by the strength, maturity and magnitude of its human evidence for the visceral-fat endpoint specifically — CT- or MRI-measured visceral adipose tissue, or DXA-estimated visceral fat — not for total weight loss or general 'metabolic health.' We separate completed human RCTs and meta-analyses from preclinical (rodent/in-vitro) data and from mechanistic extrapolation, weigh the population the evidence applies to, and grade honestly where the marketing outruns the science. Regulatory and anti-doping status are current as of June 2026.
- Human RCT evidence for visceral fat. Magnitude and quality of CT/MRI/DXA-measured visceral adipose tissue reduction in randomized controlled trials — the primary bar for this condition.
- Population applicability. Whether the visceral-fat evidence applies to the general population or only to a restricted group (e.g. HIV-associated lipodystrophy).
- Evidence maturity & availability. Phase of development, FDA-approval status, and whether the agent is legally available outside clinical trials.
- Condition-specific safety. Boxed warnings, contraindications, lean-mass loss, glucose effects, and durability of the visceral-fat benefit after discontinuation.
Rating scale: 1–5 stars, weighted toward completed human RCT/meta-analytic evidence for visceral-fat reduction specifically; preclinical-only and unproven gray-market agents are graded down regardless of marketing.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Tesamorelin (GHRH analog) | A | 5.0 | HIV-associated lipodystrophy with excess visceral abdominal fat, under clinician supervision — its approved indication | Prescription only — cost varies by insurance/pharmacy |
| 2 | Tirzepatide (dual GIP/GLP-1 agonist) | A | 4.5 | General-population type 2 diabetes or obesity seeking the largest, best-evidenced imaging-confirmed visceral-fat reduction under clinician supervision | Prescription only — cost varies by insurance/pharmacy |
| 3 | Semaglutide (GLP-1 receptor agonist) | A | 4.5 | People prioritizing broad outcome evidence and availability — strong visceral-fat reduction plus proven cardiovascular benefit | Prescription only — cost varies by insurance/pharmacy |
| 4 | Retatrutide (triple GIP/GLP-1/glucagon agonist) | A | 4.0 | Understanding where next-generation fat-loss pharmacology is heading — for reference, not for present-day use outside a trial | Investigational — not commercially available |
| 5 | GHRP / GHS 'fat-loss' peptides (ipamorelin, CJC-1295, GHRP-6, MK-677) | C | 1.5 | Understanding why the GH-axis 'fat-loss' peptides are overhyped for visceral fat — listed here to debunk, not to recommend | Not approved; sold only as 'research use only' |
Tesamorelin (GHRH analog)
The only peptide FDA-approved *specifically* to reduce visceral fat
Tesamorelin is a stabilized 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), marketed as EGRIFTA / EGRIFTA SV / EGRIFTA WR and given by daily subcutaneous injection. It is the first and only drug FDA-approved to reduce excess abdominal fat in HIV-infected patients with lipodystrophy — and its evidence base is unusual because visceral adipose tissue, measured directly by abdominal CT, was the primary efficacy endpoint rather than a substudy afterthought. Its pivotal program comprised two identical Phase 3 double-blind, placebo-controlled RCTs (~806 ART-treated adults, tesamorelin 2 mg/day vs placebo for 26 weeks), building on Falutz's landmark Phase 3 NEJM report in 2007, with visceral fat falling roughly 15–20% versus placebo. A separate MGH RCT (n=50) found visceral fat fell 34 cm² with tesamorelin versus an 8 cm² increase on placebo (net treatment effect −42 cm², p=0.005), alongside a fall in liver fat. A 2026 meta-analysis of five RCTs confirmed a significant visceral-fat reduction (mean difference −27.71 cm²), plus lower trunk fat, waist circumference and hepatic fat, without worsening glucose or lipids. The mechanism is GH-driven lipolysis acting preferentially on GH-receptor-rich visceral fat. The decisive limitation: all of this is in HIV-associated lipodystrophy; there is no adequately powered RCT in the general population, it is explicitly not approved for weight loss, and the effect reverses after discontinuation.
Strengths
- The only drug FDA-approved specifically for visceral fat, with CT-measured VAT as the primary RCT endpoint
- 2026 meta-analysis of five RCTs confirms significant visceral-fat, trunk-fat, waist and hepatic-fat reductions
- GH-driven mechanism acts preferentially on visceral fat, with little effect on subcutaneous fat and a concurrent liver-fat benefit
Weaknesses
- Approved evidence is confined to HIV-associated lipodystrophy — no adequately powered RCT in the general, non-HIV population; explicitly not approved for weight loss
- Visceral-fat loss is not sustained after discontinuation; contraindicated in pituitary tumor/surgery/radiation, active malignancy and pregnancy; can impair glucose tolerance; WADA-prohibited at all times
- Best for
- HIV-associated lipodystrophy with excess visceral abdominal fat, under clinician supervision — its approved indication
- Pricing
- Prescription only — cost varies by insurance/pharmacy
Source: Stanley et al., tesamorelin RCT, JAMA 2014 (PMC4363137)
Tirzepatide (dual GIP/GLP-1 agonist)
Largest imaging-confirmed visceral-fat loss outside HIV
Tirzepatide is a once-weekly subcutaneous dual GIP/GLP-1 receptor agonist peptide, FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea. For the general-population visceral-fat endpoint it carries the strongest imaging evidence of any agent here. The SURPASS-3 MRI substudy (n=296, type 2 diabetes) used gold-standard MRI volumetry and showed tirzepatide produced significantly greater reductions in liver fat, visceral adipose tissue and abdominal subcutaneous fat than insulin degludec — while insulin actually increased visceral fat. An exploratory z-score analysis versus UK Biobank controls suggested a targeted effect on visceral fat beyond what the magnitude of weight reduction alone would predict, a genuinely notable finding for this condition. In the SURMOUNT-1 obesity DXA substudy (n=160), tirzepatide reduced fat mass by an estimated 25.7% more than placebo, significantly cut waist circumference and visceral fat mass, and improved the proportion of lean mass relative to body weight. It reduces visceral fat by improving whole-body energy balance and insulin signaling rather than by locally targeting the abdomen. The honest caveats: predominantly GI side effects, a boxed warning for rodent thyroid C-cell tumors, reported pancreatitis and gallbladder events, meaningful lean-mass loss alongside fat loss, and regression of the benefit after discontinuation.
Strengths
- Largest MRI-confirmed visceral and liver-fat reductions outside HIV lipodystrophy (SURPASS-3), with an apparent effect beyond weight loss
- FDA-approved for type 2 diabetes, obesity and obstructive sleep apnea, with a large, mature human evidence base
- SURMOUNT-1 DXA substudy shows ~25.7% greater fat-mass reduction than placebo with improved lean-mass proportion
Weaknesses
- GI effects (nausea, diarrhea, vomiting) dominate and are titration-related; boxed warning for rodent thyroid C-cell tumors; reported pancreatitis and gallbladder events
- Meaningful lean-mass loss accompanies fat loss (resistance training and adequate protein matter); benefits largely regress after discontinuation
- Best for
- General-population type 2 diabetes or obesity seeking the largest, best-evidenced imaging-confirmed visceral-fat reduction under clinician supervision
- Pricing
- Prescription only — cost varies by insurance/pharmacy
Source: Gastaldelli et al., SURPASS-3 MRI substudy, Lancet Diabetes Endocrinol 2022 (PMID 35468325)
Semaglutide (GLP-1 receptor agonist)
Robust visceral-fat reduction plus proven cardiovascular outcomes
Semaglutide is a once-weekly subcutaneous (and once-daily oral) GLP-1 receptor agonist peptide, FDA-approved as Wegovy for obesity and cardiovascular-risk reduction and Ozempic for type 2 diabetes. For visceral fat its data are strong: the STEP 1 DXA substudy (n=140) found that with semaglutide 2.4 mg over 68 weeks, body weight fell 15.0% versus 3.6% on placebo, total fat mass fell 19.3%, and regional visceral fat mass fell 27.4% — with the proportion of lean mass increasing, i.e. preferential loss of fat and especially visceral fat. What sets semaglutide apart is outcome-level evidence: the SELECT cardiovascular-outcomes trial (17,604 adults with overweight/obesity and established CVD, no diabetes) showed a 20% reduction in major adverse cardiovascular events, leading to the first FDA cardiovascular indication for a weight-loss drug — which matters because reducing visceral fat is mechanistically tied to lowering cardiometabolic risk. Its absolute visceral-fat and total-fat reductions are somewhat smaller than tirzepatide's and retatrutide's head-to-head class trends, which is why it ranks third on visceral-fat magnitude even though it arguably leads on hard outcomes. Class caveats apply: GI effects, a thyroid C-cell tumor boxed warning, pancreatitis and gallbladder risk, lean-mass loss proportional to weight loss, and regression after stopping.
Strengths
- Robust ~27% regional visceral-fat reduction with preferential fat loss (STEP 1 DXA substudy)
- The only weight-loss drug with a proven ~20% reduction in major cardiovascular events (SELECT) — visceral-fat loss tied to hard outcomes
- FDA-approved, widely available, most broadly evidenced GLP-1, in both weekly injectable and daily oral forms
Weaknesses
- Absolute visceral-fat and total-fat reductions smaller than tirzepatide's and retatrutide's head-to-head
- Class risks: GI effects, boxed thyroid C-cell warning, pancreatitis/gallbladder risk, lean-mass loss proportional to weight loss; benefits regress after discontinuation
- Best for
- People prioritizing broad outcome evidence and availability — strong visceral-fat reduction plus proven cardiovascular benefit
- Pricing
- Prescription only — cost varies by insurance/pharmacy
Source: Wilding et al., STEP 1 body-composition substudy, J Endocr Soc 2021 (PMC8089287)
Retatrutide (triple GIP/GLP-1/glucagon agonist)
Largest fat & liver-fat reductions in class — but investigational
Retatrutide is an investigational once-weekly triple agonist (LY3437943) that activates the GIP, GLP-1 and glucagon receptors — a step beyond the dual incretin design, with the glucagon component adding energy expenditure and direct mobilization of hepatic fat. It is not FDA-approved. Its Phase 2 RCT (Jastreboff et al., NEJM 2023; n=338; 48 weeks) produced up to 24.2% mean weight loss at the 12 mg dose, and in an imaging subset liver fat fell roughly 82–86%, with over 90% of MASLD participants reaching normal liver-fat levels — the largest fat and liver-fat reductions of any agent in this class, with a DXA substudy assessing fat, lean and visceral-fat changes. Phase 3 TRIUMPH-1 topline (announced 2026) confirmed clinically meaningful weight loss across doses, up to about 25% at 80 weeks and up to about 30% in severe obesity at 104 weeks. The honest limitation dominates the ranking: as of mid-2026 retatrutide is not FDA-approved, with an NDA targeted for Q4 2026, so it is not legally available outside clinical trials — any product sold as 'retatrutide' on the gray market is unapproved and unverified. It also showed a distinct dose-dependent dysesthesia signal (up to ~21% at 12 mg) on top of the usual incretin GI effects. It earns Grade A for trial data but ranks below the approved agents on availability and maturity for the visceral-fat endpoint.
Strengths
- Largest fat and liver-fat reductions of any agent in the class (up to ~24% weight loss; ~82–86% liver-fat reduction in imaging subset)
- Triple-agonist mechanism adds glucagon-driven energy expenditure and direct hepatic-fat mobilization
- Phase 3 TRIUMPH-1 topline (2026) confirms clinically meaningful weight loss across doses
Weaknesses
- Investigational — not FDA-approved (NDA targeted Q4 2026) and not legally available outside clinical trials; gray-market versions are unapproved and unverified
- Distinct dose-dependent dysesthesia signal (up to ~21% at 12 mg) plus the usual incretin GI effects; long-term safety and dedicated visceral-fat imaging data still maturing
- Best for
- Understanding where next-generation fat-loss pharmacology is heading — for reference, not for present-day use outside a trial
- Pricing
- Investigational — not commercially available
GHRP / GHS 'fat-loss' peptides (ipamorelin, CJC-1295, GHRP-6, MK-677)
Marketed for belly fat — but no qualifying human visceral-fat RCTs
The growth-hormone-releasing peptide (GHRP) and growth-hormone-secretagogue (GHS) family — ipamorelin, CJC-1295, GHRP-6, and the oral secretagogue MK-677 (ibutamoren) — are the peptides most heavily marketed online for 'stubborn belly fat.' The rationale borrows from tesamorelin: they stimulate the growth-hormone axis, and GH is lipolytic and acts preferentially on visceral fat. But borrowing a mechanism is not the same as having the trials. None of these compounds has a qualifying human randomized controlled trial demonstrating visceral-fat reduction comparable to tesamorelin's CT-endpoint evidence — they are graded C–D for the visceral-fat endpoint specifically, and should not be equated with the approved agents above. MK-677 does raise GH and IGF-1 in humans but is associated with increased appetite, fluid retention and impaired insulin sensitivity, and it has no approved visceral-fat indication. Most of the family are WADA-prohibited as growth-hormone secretagogues or releasing factors, banned at all times in sport, and none is FDA-approved for fat loss. Their popularity rests on extrapolation and by-association reasoning, not on direct evidence for the condition. Anyone comparing them to tesamorelin, tirzepatide or semaglutide for visceral fat is comparing marketing to trial data.
Strengths
- Biologically plausible GH-lipolysis rationale (GH acts preferentially on visceral fat)
- MK-677 does measurably raise GH and IGF-1 in humans (a pharmacodynamic, not an outcome, effect)
- Widely available and inexpensive relative to the approved incretin and GHRH drugs (though this reflects lack of regulation, not proven benefit)
Weaknesses
- No qualifying human RCT for visceral-fat reduction — graded C–D; not equivalent to the approved agents' evidence
- Not FDA-approved for fat loss; most are WADA-prohibited at all times; MK-677 can worsen insulin sensitivity and cause fluid retention and appetite gain; gray-market purity is unverified
- Best for
- Understanding why the GH-axis 'fat-loss' peptides are overhyped for visceral fat — listed here to debunk, not to recommend
- Pricing
- Not approved; sold only as 'research use only'
Source: WADA Prohibited List S2 (GHRH/GHS) — Drugs.com mirror
Frequently asked
Which peptide has the best evidence specifically for visceral (belly) fat?
For the visceral-fat endpoint itself, tesamorelin has the most direct evidence — it is the only drug FDA-approved to reduce excess visceral abdominal fat, with CT-measured visceral adipose tissue as the primary outcome across multiple randomized controlled trials and a 2026 meta-analysis of five RCTs. The crucial caveat is that this evidence is confined to HIV-associated lipodystrophy; there is no adequately powered trial in the general, non-HIV population. For the general population, tirzepatide and semaglutide carry Grade A imaging-confirmed visceral-fat reduction, and tirzepatide shows the largest MRI-confirmed effect outside HIV. All are graded A for their respective evidence, but the honest answer depends on which population you belong to.
Do these drugs reduce visceral fat more than overall fat?
Yes, somewhat — visceral fat is more responsive than subcutaneous fat, but none achieves true selective 'spot reduction.' In the STEP 1 body-composition substudy, semaglutide dropped regional visceral fat by about 27% versus about 19% for total fat mass, with the proportion of lean mass actually increasing. Tirzepatide's SURPASS-3 MRI substudy suggested a targeted effect on visceral fat beyond what the degree of weight loss alone would predict. The mechanism explains the pattern: growth-hormone-driven lipolysis (tesamorelin) and incretin-driven improvements in energy balance and insulin signaling both act preferentially on the metabolically active visceral depot. But every agent reduces visceral fat as part of a systemic shift, not by locally targeting the abdomen.
Is the visceral-fat loss permanent if I stop the peptide?
No. The FDA label states plainly that tesamorelin's effect on abdominal fat is not sustained after discontinuation — the visceral fat regrows once the drug stops. Incretin-driven fat loss similarly regresses after stopping, with documented weight and visceral-fat regain. This is why these peptides are best understood as long-term adjuncts rather than cures. From a root-cause perspective, visceral fat is fundamentally driven by diet quality, sleep, alcohol, physical inactivity and the resulting hyperinsulinemia; the drugs are powerful levers layered on top of those upstream drivers, and the benefit reverses when both the foundation and the drug are removed. Durable visceral-fat reduction depends on the lifestyle changes, not the pharmacology alone.
Can I buy compounded or 'research-chemical' fat-loss peptides legally?
The picture tightened sharply in 2025–2026. The FDA's shortage-era enforcement discretion for compounded semaglutide and tirzepatide has ended (tirzepatide in early 2025, semaglutide by mid-2025), and the agency has moved to permanently exclude them from bulk compounding. Retatrutide is investigational with no legal consumer supply — any product sold as 'retatrutide' on the gray market is unapproved and unverified. The GHRP/GHS 'fat-loss' peptides (ipamorelin, CJC-1295, GHRP-6, MK-677) are unapproved and largely WADA-prohibited. Counterfeits and adverse-event reports proliferated during the shortage. Nothing here endorses gray-market or research-chemical sourcing; these are prescription or investigational medicines that belong in a legitimate medical relationship.
Do the GHRP/GHS 'fat-loss' peptides sold online reduce visceral fat?
There is no qualifying human evidence that they do. The GHRP/GHS family — ipamorelin, CJC-1295, GHRP-6, and the oral secretagogue MK-677 (ibutamoren) — stimulate the growth-hormone axis and are marketed for fat loss, but none has a human randomized controlled trial demonstrating visceral-fat reduction comparable to tesamorelin's approved evidence. They are graded C–D for this endpoint and should not be equated with the studied agents. Most are also WADA-prohibited as growth-hormone secretagogues or releasing factors, banned at all times in sport. Their popularity in biohacking circles rests on the general GH-lipolysis rationale plus tesamorelin's data by association — not on direct trials of these specific compounds for visceral fat.
Do these peptides affect anything besides waistline appearance?
Yes — visceral-fat reduction tracks with real cardiometabolic benefit, which is the deeper reason it matters. Visceral adipose tissue drives insulin resistance, dyslipidemia, fatty liver and cardiovascular risk, so shrinking it moves those risks too. Semaglutide cut major adverse cardiovascular events by about 20% in the SELECT trial, earning the first cardiovascular indication for a weight-loss drug. Tesamorelin and the incretins reduce liver fat, with tesamorelin resolving NAFLD in a meaningful fraction of HIV patients and retatrutide dropping liver fat by roughly 82–86% in an imaging subset. In other words, the visceral-fat endpoint is a proxy for cardiometabolic health, not merely cosmetic — which is exactly why the strongest evidence clusters around drugs that also improve hard outcomes.